Sign In
Buy ZYME
$22.86
-0.260 (-1.12%)
At Close: Jul 24, 2026
Wells Fargo, JPMorgan, Citigroup And Some Other Big Stocks Moving Higher On Friday
03:25pm, Friday, 14'th Oct 2022 Benzinga
U.S. stocks traded lower, with the Dow Jones gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session.
Gravitas Education Holdings, Inc. (NASDAQ: GEHI) sh
Uber, Lyft, AZZ And Other Big Losers From Tuesday
08:46am, Wednesday, 12'th Oct 2022 Benzinga
U.S. stocks closed mixed with the Nasdaq Composite dropping more than 100 points on Tuesday. Here is the list of some big stocks recording losses in the previous session.
AZZ Inc. (NYSE: AZZ) shares
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
08:30am, Monday, 03'rd Oct 2022
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announ
Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?
11:30am, Thursday, 29'th Sep 2022 Zacks Investment Research
Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
09:16am, Wednesday, 07'th Sep 2022 Benzinga
Gainers
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
IVERIC bio, Inc. (NASDAQ: ISEE) rose 66.3% to close at $15.70
Zymeworks Inc. (ZYME) CEO Ken Galbraith on Q2 2022 Results - Earnings Call Transcript
07:43pm, Saturday, 06'th Aug 2022
Zymeworks Inc. (NYSE:ZYME ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Jack Spinks - Associate Director of Investor Relations Ken Galbraith - Chair and CEO Dr. Neil
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
12:35am, Friday, 05'th Aug 2022 Zacks Investment Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -4.30% and 34.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
09:49pm, Thursday, 04'th Aug 2022
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -4.30% and 34.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Announces Participation in Upcoming Investor Conferences
08:30am, Monday, 01'st Aug 2022
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announ
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
12:45pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 26.23% and 8.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting
12:54pm, Sunday, 29'th May 2022 MarketWatch
This includes Arcellx, Iovance Biotherapeutics, and ZymeWorks.
Analyst Ratings for Zymeworks
03:45pm, Friday, 27'th May 2022 Benzinga
Over the past 3 months, 5 analysts have published their opinion on Zymeworks (NYSE:ZYME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company
Zymeworks Announces Participation in Upcoming Investor Conference
05:30am, Friday, 27'th May 2022
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announ
Zymeworks rejects 'unsolicited, opportunistic' buyout bid by UAE-based All Blue Falcons
09:53am, Friday, 20'th May 2022
Shares of Zymeworks Inc. ZYME, +1.89% rallied 1.5% in morning trading Friday, after the biopharmaceutical company said it rejected the "unsolicited, opportunistic, non-binding" $10.50-per-share buyout
Zymeworks And The Blue Falcon Elucidation
03:36pm, Tuesday, 17'th May 2022
Zymeworks shares have fallen, but the pipeline remains intact. Moreover, a special situation is brewing.
